A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer

This study tests a new drug called TD001 — a targeted radiotherapy that homes in on prostate cancer cells using a protein they display on their surface (called PSMA) — in men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. **You may be eligible if...** - You have metastatic castration-resistant prostate cancer (prostate cancer that has spread and stopped responding to hormone therapy) - Your cancer cells express the PSMA protein - You have at least one measurable tumor site - You have already received hormone therapy and at least one androgen receptor pathway inhibitor drug **You may NOT be eligible if...** - You received certain radioactive treatments in the past 6 months - You had recent systemic cancer treatment (within 28 days) - You have known allergy to TD001 or similar compounds - You require continuous oxygen therapy or have severe lung disease Talk to your doctor to see if this trial is right for you.